Cardiosphere-derived cells show strong immunomodulatory activity and improve muscle physiology when systemically delivered in a DMD mouse model

      Cardiosphere-Derived Cells (CDCs) modulate inflammation, limit fibrosis, and promote tissue regeneration in myocardial infarction models. Intramyocardial administration of CDCs improves cardiac function and increases long-term survival in aged mdx mice. These results motivated the HOPE-Duchenne clinical trial to treat Duchenne muscular dystrophy (DMD)-associated cardiomyopathy by intracoronary delivery of allogeneic CDCs. The positive results observed in HOPE justify additional studies for exploring new delivery routes and regimens that can maximize the efficacy of the CDCs, allow for multiple administrations, and reduce patient administration discomfort. In addition, a better understanding of the mechanisms of action of CDCs will be extremely useful for improving potency of the product. Here we analyzed the immunomodulatory capabilities of CDCs and studied the efficacy and biodistribution of CDCs when delivered systemically.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect